![](https://www.businessmarketinsights.com/assets/img/reports-icon.png)
Nordamerika Point-of-Care-Marktprognose für molekulare Diagnostik bis 2028 – Auswirkungen von COVID-19 und regionale Analyse nach Produkten und Dienstleistungen (Assays und Kits, Instrumente sowie Dienstleistungen und Software), Technologie (PCR, isotherme Nukleinsäureamplifikationstechnologie (INAAT)) und andere Technologien), Anwendung (Infektionskrankheiten, Onkologie, Hämatologie, pränatale Tests, Endokrinologie und andere Anwendungen), Endbenutzer (Krankenhäuser und Kliniken, Diagnoselabore, Forschungs- und akademische Institute und andere)
Markteinführung
Point-of-Care-Molekulardiagnostik umfasst tragbare Geräte sowie Tests und Tests ; Kits zur Erkennung und Diagnose von Krankheiten in menschlichen Proben wie Rachenabstrich, Blut, Serum und Stuhl. Die molekulare Diagnostik verlagert sich von zentralisierten Laboren hin zu dezentralen molekularen Tests am Behandlungsort. Aufgrund seiner Einfachheit, Bequemlichkeit, schnellen Bearbeitungszeit und dem Potenzial, die Patientenergebnisse zu verbessern, gewinnt POCT schnell an Bedeutung.
Darüber hinaus wächst die Nachfrage nach spezifischen, verbrauchenden Virusnachweismethoden Es wird erwartet, dass weniger Zeit für eine rechtzeitige Infektionskontrolle das Marktwachstum im Prognosezeitraum ankurbeln wird.
Die USA haben die höchste Anzahl an COVID-19-Fällen aller Länder in Nordamerika. Dies hat sich negativ auf verschiedene Branchen sowie Liefer- und Vertriebsketten in der Region ausgewirkt. Während der Pandemie verlagerten Life-Science-Unternehmen ihren Schwerpunkt auf die Entwicklung neuartiger Medikamente zur Behandlung lebensbedrohlicher Krankheiten. Darüber hinaus ist auch die Nachfrage nach Schnelltestgeräten gestiegen, was eine herausragende Rolle beim Wachstum des nordamerikanischen Marktes für Point-of-Care-Molekulardiagnostik spielt. Darüber hinaus steigert die anhaltende Verbreitung von COVID-19 die Nachfrage nach Point-of-Care-Molekulardiagnostik-Kits. Die Einführung dieser Kits fördert die Entwicklung und Einführung neuer Produkte. Im März 2021 erhielt Eurofins‘ Clinical Enterprise, Inc. von der US-amerikanischen Food and Drug Administration (FDA) eine Notfallzulassung (Emergency Use Authorization, EUA) für eine Direct-to-Consumer-Version (DTC) seines EmpowerDX COVID-19 Home Collection Kit. In ähnlicher Weise kündigte Clinical Diagnostics von Eurofins USA im Juli 2020 die Verfügbarkeit seines gepoolten PCR-Tests zum Nachweis von SARS-CoV-2 an, der die Kosten pro PCR-Test für Kunden erheblich senken würde.
Marktüberblick und Dynamik
Es wird erwartet, dass der Markt für Point-of-Care-Molekulardiagnostik in Nordamerika an Bedeutung gewinnt 2.110,1 Millionen US-Dollar bis 2028 gegenüber 860,9 Millionen US-Dollar im Jahr 2021. Es wird geschätzt, dass der Markt von 2021 bis 2028 mit einer jährlichen Wachstumsrate von 13,7 % wachsen wird. Die anhaltende COVID-19-Pandemie hat auch Chancen für die Hersteller von POC-Molekulardiagnostik-Kits zum Nachweis des neuartigen Coronavirus geschaffen. Beispielsweise hat ABBOTT, ein globaler Hersteller von Gesundheits- und Medizingeräten, ID NOW auf den Markt gebracht. Es handelt sich um ein molekulares Point-of-Care-Instrument zur Erkennung neuer Coronavirus-Infektionen in weniger als fünf Minuten. ID NOW ist eine schnelle, instrumentenbasierte, isotherme Technik zur qualitativen Erkennung von Infektionskrankheiten. Sein proprietäres Produkt zur isothermen Nukleinsäureamplifikation & Services generiert in Sekundenschnelle molekulare Daten und ermöglicht es Ärzten, während eines Patientenbesuchs evidenzbasierte Behandlungsentscheidungen zu treffen. Der ID NOW wurde nicht von der Food and Drug Administration (FDA) zertifiziert oder zugelassen. Es wurde von der FDA im Rahmen einer Notfallzulassung (Emergency Use Authorization, EUA) für die Verwendung in autorisierten Labors und Patientenversorgungseinrichtungen zugelassen. Es wird erwartet, dass solche Innovationen und Produktentwicklungen im Prognosezeitraum lukrative Chancen für das Wachstum des nordamerikanischen Marktes für Point-of-Care-Molekulardiagnostik bieten.
Wichtige Marktsegmente
In Bezug auf Produkt & Im Bereich der Dienstleistungen hatte das Segment „Assays und Kits“ im Jahr 2020 den größten Anteil am Markt für Point-of-Care-Molekulardiagnostik in Nordamerika. In Bezug auf die Technologie hatte das Segment PCR den größten Anteil am Markt für Point-of-Care-Molekulardiagnostik in Nordamerika Diagnostikmarkt im Jahr 2020. In Bezug auf die Anwendung hatte das Segment Infektionskrankheiten im Jahr 2020 den größten Anteil am nordamerikanischen Point-of-Care-Molekulardiagnostikmarkt. In Bezug auf den Endverbraucher hatte das Segment Diagnoselabore den größten Anteil der nordamerikanische Markt für molekulare Point-of-Care-Diagnostik im Jahr 2020.
Wichtige Quellen und Unternehmen aufgeführt
Einige wichtige primäre und sekundäre Quellen, auf die bei der Erstellung dieses Berichts über den Point-of-Care-Molekulardiagnostik-Markt in Nordamerika Bezug genommen wird, sind Unternehmenswebsites, Jahresberichte, Finanzberichte und nationale Regierungsdokumente und statistische Datenbank, unter anderem. Zu den wichtigsten im Bericht aufgeführten Unternehmen gehören bioMérieux SA, F. Hoffmann-La Roche Ltd., Danaher Corporation, Enzo Biochem, Inc., Abbott, binx health, Inc., Meridian BioScience, Inc., Biocartis, Quidel Corporation und Bio-Rad Laboratories, Inc.
Bericht über Kaufgründe
- Um die Marktlandschaft für Point-of-Care-Molekulardiagnostik in Nordamerika zu verstehen und Marktsegmente zu identifizieren, die wahrscheinlich eine starke Rendite garantieren
- Um die sich ständig verändernde Marktlandschaft zu verstehen und im Wettbewerb vorne zu bleiben
- Um Fusionen und Übernahmen sowie Partnerschaftsabkommen im Norden effizient zu planen Markt für Point-of-Care-Molekulardiagnostik in Amerika durch Identifizierung von Segmenten mit den vielversprechendsten wahrscheinlichen Verkäufen
- Um fundierte Geschäftsentscheidungen auf der Grundlage einer scharfsinnigen und umfassenden Analyse der Marktleistung verschiedener Segmente zu treffen
- Um eine Marktumsatzprognose für den Point-of-Care-Molekulardiagnostik-Markt in Nordamerika basierend auf verschiedenen Segmenten für den Zeitraum 2021–2028 zu erhalten
NORDAMERIKA POINT-OF-CARE-MARKTSEGMENTIERUNG FÜR MOLEKULARE DIAGNOSTIK
Nach Produkt & ; Dienstleistungen
- Assays und Kits
- Instrumente
- Dienste und Software
Nach Technologie
- PCR
- Isothermale Nukleinsäureamplifikationstechnologie (INAAT)
- Andere Technologien
Von Anwendung
- Infektionskrankheiten
- Onkologie
- Hämatologie
- Pränatale Tests
- Endokrinologie
- Andere Anwendungen
Von Endbenutzer
- Krankenhäuser und Kliniken
- Diagnoselabore
- Forschungs- und akademische Institute
- Andere
Nach Land
- Nordamerika
- USA
- Kanada
- Mexiko
Erwähnte Unternehmen
- bioMérieux SA
- F. Hoffmann-La Roche Ltd.
- Danaher Corporation
- Enzo Biochem, Inc.
- Abbott
- binx health, Inc.
- Meridian BioScience, Inc.
- Biocartis
- Quidel Corporation
- Bio-Rad Laboratories, Inc.
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 North America Point-of-Care Molecular Diagnostics Market – By Product & Services
1.3.2 North America Point-of-Care Molecular Diagnostics Market – By Technology
1.3.3 North America Point-of-Care Molecular Diagnostics Market – By Application
1.3.4 North America Point-of-Care Molecular Diagnostics Market – By End User
1.3.5 North America Point-of-Care Molecular Diagnostics Market– By Geography
2. North America Point-of-Care Molecular Diagnostics Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Point-of-Care Molecular Diagnostics Market– Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 North America – PEST Analysis
4.3 Experts Opinion
5. Point-of-Care Molecular Diagnostics Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Growing Demand for Specific Viral Detection Methods that Consume Less Time for Timely Infection Control
5.1.2 Rising Incidences of Infectious Diseases
5.2 Market Restraints
5.2.1 Pricing Pressures owing to Reimbursement Cuts
5.3 Market Opportunities
5.3.1 Rising R&D and Innovation in Point-of-Care Molecular Diagnostics
5.4 Future Trends
5.4.1 Rising Implementation of Molecular Point-of-Care Diagnostic Devices and Kits across Residential Setting
5.5 Impact Analysis
6. Point-of-Care Molecular Diagnostics Market– North America Analysis
6.1 North America Point-of-Care Molecular Diagnostics Market Revenue Forecast and Analysis
7. Point-of-Care Molecular Diagnostics Market Analysis and Forecast to 2028 – By Product & services
7.1 Overview
7.2 Point-of-Care Molecular Diagnostics Market, by Product & services 2020 & 2028 (%)
7.3 Assays and Kits
7.3.1 Overview
7.3.2 Assays and Kits: Point-of-Care Molecular Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
7.4 Instruments
7.4.1 Overview
7.4.2 Instruments: Point-of-Care Molecular Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
7.5 Services and Software
7.5.1 Overview
7.5.2 Services and Software: Point-of-Care Molecular Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
8. Point-of-Care Molecular Diagnostics Market Analysis and Forecast to 2028 – By Technology
8.1 Overview
8.2 Point-of-Care Molecular Diagnostics Market, by Technology 2020 & 2028 (%)
8.3 PCR
8.3.1 Overview
8.3.2 PCR: Point-of-Care Molecular Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
8.4 Isothermal Nucleic Acid Amplification Technology (INAAT)
8.4.1 Overview
8.4.2 Isothermal Nucleic Acid Amplification Technology: Point-of-Care Molecular Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
8.5 Others
8.5.1 Overview
8.5.2 Others: Point-of-Care Molecular Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
9. Point-of-Care Molecular Diagnostics Market Analysis – By Application
9.1 Overview
9.2 Point-of-Care Molecular Diagnostics Market, by Application 2020 & 2028 (%)
9.3 Infectious Disease
9.3.1 Overview
9.3.2 Infectious Disease: Point-of-Care Molecular Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
9.4 Oncology
9.4.1 Overview
9.4.2 Oncology: Point-of-Care Molecular Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
9.5 Hematology
9.5.1 Overview
9.5.2 Hematology: Point-of-Care Molecular Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
9.6 Prenatal Testing
9.6.1 Overview
9.6.2 Prenatal Testing: Point-of-Care Molecular Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
9.7 Endocrinology
9.7.1 Overview
9.7.2 Endocrinology: Point-of-Care Molecular Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
9.8 Others
9.8.1 Overview
9.8.2 Others: Point-of-Care Molecular Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
10. Point-of-Care Molecular Diagnostics Market Analysis and Forecast to 2028 – By End User
10.1 Overview
10.2 Point-of-Care Molecular Diagnostics Market, by End User 2020 & 2028 (%)
10.3 Hospitals and Clinics
10.3.1 Overview
10.3.2 Hospitals and Clinics: Point-of-Care Molecular Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
10.4 Diagnostic Laboratories
10.4.1 Overview
10.4.2 Diagnostic Laboratories: Point-of-Care Molecular Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
10.5 Research and Academic Institutes
10.5.1 Overview
10.5.2 Research and Academic Institutes: Point-of-Care Molecular Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
10.6 Others
10.6.1 Overview
10.6.2 Others: Point-of-Care Molecular Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
11. North America Point-of-Care Molecular Diagnostics Market – Geographic Analysis
11.1 North America: Point-of-Care Molecular Diagnostics Market
11.1.1 Overview
11.1.2 North America: Point-of-Care Molecular Diagnostics Market - Revenue and Forecast to 2028 (USD Million)
11.1.3 North America Point-of-Care Molecular Diagnostics Market, by Product & services – Revenue and Forecast to 2028 (USD Million)
11.1.4 North America Point-of-Care Molecular Diagnostics Market, by Technology – Revenue and Forecast to 2028 (USD Million)
11.1.5 North America Point-of-Care Molecular Diagnostics Market, by Application– Revenue and Forecast to 2028 (USD Million)
11.1.6 North America Point-of-Care Molecular Diagnostics Market, by End User – Revenue and Forecast to 2028 (USD Million)
11.1.7 North America: Point-of-Care Molecular Diagnostics Market, by Country, 2021 & 2028 (%)
11.1.7.1 US: Point-of-Care Molecular Diagnostics Market – Revenue and Forecast to 2028 (USD Million)
11.1.7.1.1 US: Point-of-Care Molecular Diagnostics Market – Revenue and Forecast to 2028 (USD Million)
11.1.7.1.2 US Point-of-Care Molecular Diagnostics Market, by Product & services – Revenue and Forecast to 2028 (USD Million)
11.1.7.1.3 US Point-of-Care Molecular Diagnostics Market, by Technology – Revenue and Forecast to 2028 (USD Million)
11.1.7.1.4 US Point-of-Care Molecular Diagnostics Market, by Application– Revenue and Forecast to 2028 (USD Million)
11.1.7.1.5 US Point-of-Care Molecular Diagnostics Market, by End User – Revenue and Forecast to 2028 (USD Million)
11.1.7.2 Canada: Point-of-Care Molecular Diagnostics Market – Revenue and Forecast to 2028 (USD Million)
11.1.7.2.1 Canada: Point-of-Care Molecular Diagnostics Market – Revenue and Forecast to 2028 (USD Million)
11.1.7.2.2 Canada Point-of-Care Molecular Diagnostics Market, by Product & services – Revenue and Forecast to 2028 (USD Million)
11.1.7.2.3 Canada Point-of-Care Molecular Diagnostics Market, by Technology – Revenue and Forecast to 2028 (USD Million)
11.1.7.2.4 Canada Point-of-Care Molecular Diagnostics Market, by Application– Revenue and Forecast to 2028 (USD Million)
11.1.7.2.5 Canada Point-of-Care Molecular Diagnostics Market, by End User – Revenue and Forecast to 2028 (USD Million)
11.1.7.3 Mexico: Point-of-Care Molecular Diagnostics Market – Revenue and Forecast to 2028 (USD Million)
11.1.7.3.1 Mexico: Point-of-Care Molecular Diagnostics Market – Revenue and Forecast to 2028 (USD Million)
11.1.7.3.2 Mexico Point-of-Care Molecular Diagnostics Market, by Product & services – Revenue and Forecast to 2028 (USD Million)
11.1.7.3.3 Mexico Point-of-Care Molecular Diagnostics Market, by Technology – Revenue and Forecast to 2028 (USD Million)
11.1.7.3.4 Mexico Point-of-Care Molecular Diagnostics Market, by Application– Revenue and Forecast to 2028 (USD Million)
11.1.7.3.5 Mexico Point-of-Care Molecular Diagnostics Market, by End User – Revenue and Forecast to 2028 (USD Million)
12. Impact Of COVID-19 Pandemic on Point-of-Care Molecular Diagnostics Market
12.1 North America: Impact Assessment of COVID-19 Pandemic
13. Point-of-Care Molecular Diagnostics Market– Industry Landscape
13.1 Overview
13.2 Growth Strategies in the Point-of-Care Molecular Diagnostics Market, 2018-2021
13.3 Organic Growth Strategies
13.3.1 Overview
13.4 Inorganic Growth Strategies
13.4.1 Overview
14. Company Profiles
14.1 F. Hoffmann-La Roche Ltd.
14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 Key Developments
14.2 bioMérieux SA
14.2.1 Key Facts
14.2.2 Business Description
14.2.3 Products and Services
14.2.4 Financial Overview
14.2.5 SWOT Analysis
14.2.6 Key Developments
14.3 Abbott
14.3.1 Key Facts
14.3.2 Business Description
14.3.3 Products and Services
14.3.4 Financial Overview
14.3.5 SWOT Analysis
14.3.6 Key Developments
14.4 MERIDIAN BIOSCIENCE, INC.
14.4.1 Key Facts
14.4.2 Business Description
14.4.3 Products and Services
14.4.4 Financial Overview
14.4.5 SWOT Analysis
14.4.6 Key Developments
14.5 Enzo Biochem Inc.
14.5.1 Key Facts
14.5.2 Business Description
14.5.3 Products and Services
14.5.4 Financial Overview
14.5.5 SWOT Analysis
14.5.6 Key Developments
14.6 Biocartis
14.6.1 Key Facts
14.6.2 Business Description
14.6.3 Products and Services
14.6.4 Financial Overview
14.6.5 SWOT Analysis
14.6.6 Key Developments
14.7 Quidel Corporation
14.7.1 Key Facts
14.7.2 Business Description
14.7.3 Products and Services
14.7.4 Financial Overview
14.7.5 SWOT Analysis
14.7.6 Key Developments
14.8 Danaher
14.8.1 Key Facts
14.8.2 Business Description
14.8.3 Products and Services
14.8.4 Financial Overview
14.8.5 SWOT Analysis
14.8.6 Key Developments
14.9 BIO-RAD LABORATORIES INC.
14.9.1 Key Facts
14.9.2 Business Description
14.9.3 Products and Services
14.9.4 Financial Overview
14.9.5 SWOT Analysis
14.9.6 Key Developments
14.10 binx health, inc.
14.10.1 Key Facts
14.10.2 Business Description
14.10.3 Products and Services
14.10.4 Financial Overview
14.10.5 SWOT Analysis
14.10.6 Key Developments
15. Appendix
15.1 About The Insight Partners
15.2 Glossary of Terms
LIST OF TABLES
Table 1. North America Point-of-Care Molecular Diagnostics Market, by Product & services – Revenue and Forecast to 2028 (USD Million)
Table 2. North America Point-of-Care Molecular Diagnostics Market, by Technology – Revenue and Forecast to 2028 (USD Million)
Table 3. North America Point-of-Care Molecular Diagnostics Market, by Application– Revenue and Forecast to 2028 (USD Million)
Table 4. North America Point-of-Care Molecular Diagnostics Market, by End User – Revenue and Forecast to 2028 (USD Million)
Table 5. US Point-of-Care Molecular Diagnostics Market, by Product & services – Revenue and Forecast to 2028 (USD Million)
Table 6. US Point-of-Care Molecular Diagnostics Market, by Technology – Revenue and Forecast to 2028 (USD Million)
Table 7. US Point-of-Care Molecular Diagnostics Market, by Application– Revenue and Forecast to 2028 (USD Million)
Table 8. US Point-of-Care Molecular Diagnostics Market, by End User – Revenue and Forecast to 2028 (USD Million)
Table 9. Canada Point-of-Care Molecular Diagnostics Market, by Product & services -Revenue and Forecast to 2028 (USD Million)
Table 10. Canada Point-of-Care Molecular Diagnostics Market, by Technology – Revenue and Forecast to 2028 (USD Million)
Table 11. Canada Point-of-Care Molecular Diagnostics Market, by Application– Revenue and Forecast to 2028 (USD Million)
Table 12. Canada Point-of-Care Molecular Diagnostics Market, by End User – Revenue and Forecast to 2028 (USD Million)
Table 13. Mexico Point-of-Care Molecular Diagnostics Market, by Product & services -Revenue and Forecast to 2028 (USD Million)
Table 14. Mexico Point-of-Care Molecular Diagnostics Market, by Technology – Revenue and Forecast to 2028 (USD Million)
Table 15. Mexico Point-of-Care Molecular Diagnostics Market, by Application– Revenue and Forecast to 2028 (USD Million)
Table 16. Mexico Point-of-Care Molecular Diagnostics Market, by End User – Revenue and Forecast to 2028 (USD Million)
Table 17. Recent Organic Developments the Point-of-Care Molecular Diagnostics Market
Table 18. Recent Inorganic Developments in the Point-of-Care Molecular Diagnostics Market
Table 19. Glossary of Terms, Point-of-Care Molecular Diagnostics Market
LIST OF FIGURES
Figure 1. Point-of-Care Molecular Diagnostics Market Segmentation
Figure 2. North America Point-of-Care Molecular Diagnostics Market Overview
Figure 3. Assays and Kits Segment Held the Largest Share by Product & services in North America Point-of-Care Molecular Diagnostics Market
Figure 4. US to Show Significant Growth During Forecast Period
Figure 5. North America Point-of-Care Molecular Diagnostics Market, Industry Landscape
Figure 6. North America PEST Analysis
Figure 7. North America Point-of-Care Molecular Diagnostics Market– Revenue Forecast and Analysis – 2020- 2028
Figure 8. Point-of-Care Molecular Diagnostics Market, by Product & services 2020 & 2028 (%)
Figure 9. Assays and Kits: Point-of-Care Molecular Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 10. Instruments: Point-of-Care Molecular Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 11. Services and Software: Point-of-Care Molecular Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 12. Point-of-Care Molecular Diagnostics Market, by Technology 2020 & 2028 (%)
Figure 13. PCR: Point-of-Care Molecular Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 14. Isothermal Nucleic Acid Amplification Technology: Point-of-Care Molecular Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 15. Others: Point-of-Care Molecular Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 16. Point-of-Care Molecular Diagnostics Market, by Application 2020 & 2028 (%)
Figure 17. Infectious Disease: Point-of-Care Molecular Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 18. Oncology: Point-of-Care Molecular Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 19. Hematology: Point-of-Care Molecular Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 20. Prenatal Testing: Point-of-Care Molecular Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 21. Endocrinology: Point-of-Care Molecular Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 22. Others: Point-of-Care Molecular Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 23. Point-of-Care Molecular Diagnostics Market, by End User 2020 & 2028 (%)
Figure 24. Hospitals and Clinics: Point-of-Care Molecular Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 25. Diagnostic Laboratories: Point-of-Care Molecular Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 26. Research and Academic Institutes: Point-of-Care Molecular Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 27. Others: Point-of-Care Molecular Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)
Figure 28. North America: Point-of-Care Molecular Diagnostics Market, by Key Country – Revenue (2021) (USD Million)
Figure 29. North America Point-of-Care Molecular Diagnostics Market Revenue and Forecast to 2028 (USD Million)
Figure 30. North America: Point-of-Care Molecular Diagnostics Market, by Country, 2021 & 2028 (%)
Figure 31. US: Point-of-Care Molecular Diagnostics Market – Revenue and Forecast to 2028 (USD Million)
Figure 32. Canada: Point-of-Care Molecular Diagnostics Market – Revenue and Forecast to 2028 (USD Million)
Figure 33. Mexico: Point-of-Care Molecular Diagnostics Market – Revenue and Forecast to 2028 (USD Million)
Figure 34. Impact of COVID-19 Pandemic on Point-of-Care Molecular Diagnostic Market in North America
Figure 35. Growth Strategies in the Point-of-Care Molecular Diagnostics Market, 2018-2021
- bioMérieux SA
- F. Hoffmann-La Roche Ltd.
- Danaher Corporation
- Enzo Biochem, Inc.
- Abbott
- binx health, Inc.
- Meridian BioScience, Inc.
- Biocartis
- Quidel Corporation
- Bio-Rad Laboratories, Inc.
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America Point-of-Care molecular diagnostics market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the North America Point-of-Care molecular diagnostics market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.